Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study
NCT05430854
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
155
Enrollment
INDUSTRY
Sponsor class
Stopped
Sponsor Decision
Conditions
Systemic Lupus Erythematosus
Interventions
BIOLOGICAL:
Daxdilimab
Sponsor
Amgen